(E) Immunoblot showing phospho-SMAD2/3 and SMAD2/3 expression in control and IPF fibroblasts treated for 30 min with TGF-β1 after 48 hr transfection with PRRX1 siRNA. This evidence concerns the gene SMAD2 and idiopathic pulmonary fibrosis.